Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT known ✓ | P10721 | 7/20 | 0.97 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.97 |
| ▸ | FGFR3 known ✓ | P22607 | 2/20 | 0.97 |
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 0.67 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.65 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.65 |
| ▸ | TOP2A known ✓ | P11388 | 1/20 | 0.65 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.42 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | TLR3 | O15455 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060598 | 0.99 | KIT (1.00) | KITPDGFRAFGFR3KDM4EMEN1 | |
| SCHEMBL564035 | 0.99 | KIT (1.00) | KITPDGFRAFGFR3KDM4EMEN1 | |
| Bromide SCHEMBL10413309 | 0.97 | KIT (0.97) | KITPDGFRAFGFR3KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL15517783 | 0.97 | KIT (0.97) | KITPDGFRAFGFR3KDM4EMEN1 | |
| SCHEMBL27170417 | 0.88 | KIT (0.81) | KITPDGFRAFGFR3KDM4EMEN1 | |
| SCHEMBL17212473 | 0.85 | KIT (0.76) | KITPDGFRAFGFR3KDM4EMEN1 | |
| SCHEMBL31362096 | 0.83 | KIT (1.00) | KITPDGFRAFGFR3KDM4EMEN1 | |
| SCHEMBL3342543 | 0.83 | KIT (0.72) | KITPDGFRAFGFR3KDM4EMEN1 | |
| SCHEMBL27807938 | 0.83 | KIT (1.00) | KITPDGFRAFGFR3KDM4EMEN1 | |
| SCHEMBL29132000 | 0.82 | KIT (0.71) | KITPDGFRAFGFR3KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304580-A2 | METHODS FOR APPLYING TUMOR TREATING FIELDS IN COMBINATION WITH CANCER TREATING THERAPEUTICS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20220288404-A1 | METHODS FOR APPLYING TUMOR TREATING FIELDS IN COMBINATION WITH CANCER TREATING THERAPEUTICS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2022192719-A2 | METHODS FOR APPLYING TUMOR TREATING FIELDS IN COMBINATION WITH CANCER TREATING THERAPEUTICS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-1042731-C | Ellipticine derivative and process for preparing the same | TANABE SEIYAKU CO (JP) | 1999-03-31 | — | — | CN | disclosed |
| WO-1997046559-A1 | PROCESS FOR PREPARING 9-HYDROXYELLIPTICINE | TANABE SEIYAKU CO., LTD. (JP) | 1997-12-11 | — | — | WO | disclosed |
| US-5605904-A | ANTITUMOR AGENTS; ANTICARCINOGENIC AGENTS; FEWER SIDE EFFECTS | TANABE SEIYAKU CO., LTD. (JP) | 1997-02-25 | — | — | US | disclosed |
| US-5565569-A | ANTITUMOR AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1996-10-15 | — | — | US | disclosed |
| CN-1099034-A | ellipticine derivative and preparation method thereof | TANABE SEIYAKU CO (JP) | 1995-02-22 | — | — | CN | disclosed |
| EP-0608876-A1 | Ellipticine derivatives with antitumour activity | TANABE SEIYAKU CO., LTD. (JP) | 1994-08-03 | — | — | EP | disclosed |
| US-3933827-A | CYTOSTATIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1976-01-20 | — | — | US | disclosed |